Smith & Nephew disposes of rehabilitation business for $123 million
This article was originally published in Clinica
UK company Smith & Nephew has sold its rehabilitation business to AbilityOne for £87 million ($123 million). S&N will retain a 21.5% interest in the business. AbilityOne is a portfolio company of One Equity Partners and the leading supplier of rehabilitation products in the US.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.